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Abstract 
Background: Simultaneous multipolar ablation catheters have been proposed to simplify 
pulmonary vein isolation (PVI) in paroxysmal atrial fibrillation (AF). Recently a new multipolar 
irrigated radiofrequency (RF) ablation catheter (nMARQ
TM
,
 
Biosense Webster Inc, Diamond Bar, 
California) combining both three-dimensional electroanatomic mapping and multipolar open-
irrigated ablation capability has been developed. Aim of our study was to assess feasibility, acute 
and short term success and safety of PVI by the use of this new technology with particular regard 
to the incidence of post-ablation silent cerebral ischemia (SCI).  
Methods and Results: Twenty-five patients (76% males; age 57±13 years) with paroxysmal AF 
underwent PVI using the nMARQ
TM  
catheter. PVI, confirmed by Lasso catheter mapping, was 
achieved in 100 out of 102 pulmonary veins (98%) identified and final PVI was obtained in 24 
out of 25 (96%) patients. The overall concordance between Lasso and nMARQ
TM
 signals in 
demonstrating PVI was 78%. No major procedural complications, occurred and no patient 
suffered SCI, on the basis of cerebral magnetic resonance imaging (MRI) performed before and 
after the procedure. Following a six-month follow-up 17/25 (68%) patients remained free from 
AF without antiarrhythmic drugs.  
Conclusions: In our preliminary experience, PVI with nMARQ
TM
 catheter appears to be feasible  
and safe, without incidence of SCI. Long term clinical efficacy has to be evaluated in further 
studies. 
 
Key-words: pulmonary vein isolation; atrial fibrillation; ablation; silent cerebral ischemia; 
asyntomatic cerebral embolism; nMARQ
TM
; signals 
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Introduction 
Pulmonary vein isolation (PVI) is a well-established treatment for symptomatic paroxysmal 
atrial fibrillation (AF) and can be considered as a first-line therapy in patients with structurally 
normal heart.
1
  However, the generally used “point by point” ablation technique to isolate 
pulmonary veins (PVs) is still time consuming and requires experienced operators to perform 
and create reliable contiguous transmural lesions. In order to overcome these limitations, a 
simultaneous multipolar nonirrigated radiofrequency (RF) ablation catheter has been introduced 
in clinical practice.
2
  Unfortunately the use of this catheter has been correlated with a high 
incidence of silent cerebral ischemia (SCI).
3,4
  Recently a new catheter (nMARQ
TM
 Circular, 
Biosense Webster Inc, Diamond Bar, California) combining both 3D electroanatomic mapping 
(EAM) and multipolar RF ablation capability through open-irrigation design has recently been 
developed.  Preliminary reports on PVI with nMARQ
TM
 showed a good acute success but still 
with a high incidence of complications such as SCI and atrio-esophageal fistulas.
5,6,7
 
Moreover, most of these preliminary studies did not provide confirmation of PVI with the 
standard circular multipolar mapping method and did not strictly apply the methodology 
proposed at the present time to reduce the incidence of SCI using the RF multielectrode ablation 
catheter.
8
 
The present study aimed to assess, in patients with paroxysmal AF undergoing PVI with the use 
of this new catheter, the followings: 1) feasibility; 2) acute success validated with the Lasso 
catheter (BiosenseWebster, Diamond Bar, USA); 3) safety with particular interest on the 
incidence of periprocedural SCI by performing cerebral diffusion-weighted magnetic resonance 
imaging (DW-MRI) before and after the procedure; 4) short term follow-up (6 months). 
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Methods 
Study Population and Protocol 
Twenty-five consecutive patients with drug-refractory paroxysmal AF undergoing PVI were 
prospectively enrolled. Exclusion criteria were: age <20 and >80 years, severe valvular heart 
disease, acute coronary syndrome in the last 3 months, previous AF catheter ablation, previous 
pacemaker or implantable cardioverter-defibrillator implant, any contraindication to cerebral 
MRI. All patients gave written informed consent before enrollment.  
On admission all patients underwent a thorough cardiac assessment including transesophageal 
echocardiogram. All the patients underwent cerebral MRI 24 hours before and 24 hours after the 
ablation. The antithrombotic therapy was discontinued 5 days before admission and replaced by 
low molecular weight heparin (LMWH) dosed according to the body weight (1 mg/kg BD), until 
12 hours before the procedure.  
Cerebral MRI Imaging 
Cerebral MRI was performed, using a 1.5 T scanner (1.5 Tesla Magnetom Avanto, Siemens, 
Erlangen, Germany).  The detailed cerebral MRI imaging protocol has been previously reported
9
. 
Briefly, the imaging protocol included a sagittal T1-weighted spin echo sequence; an axial fluid-
attenuated inversion recovery (FLAIR) sequence; a diffusion-weighted (DW) sequence. In the 
postablation MRI, acute embolic lesion was defined as a new focal hyperintense area detected by 
the FLAIR sequence, corresponding to a restricted diffusion signal in the DW sequence and 
confirmed by the apparent diffusion coefficient mapping to rule out a shine through artifact. The 
size and the location of the focal lesions were analyzed. Two blinded certified radiologists 
independently analyzed all MRI images. Interobserver variability for the MRI assessment was 
tested with the McNemar test and was not statistically significant. 
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Ablation Procedure: General Protocol 
A contrast-enhanced cardiac MRI of the left atrium (LA) was performed 24 hours before the AF 
ablation. Deep sedation was achieved by means of intravenous fentanyl, midazolam and 
propofol.  
Through femoral vein access, a decapolar electrode catheter was inserted into the coronary sinus. 
The LA was accessed by a single transseptal puncture using an 8.5 F long sheath continuously 
perfused with heparinized solution. Intravenous unfractionated heparin (100 IU/kg) was 
administered as follows: a third of the dose after femoral access and two-thirds of dose 
immediately after the transseptal puncture. The activated clotting time (ACT) was determined 
every 30 min and additional boluses were administered aiming to maintain ACT >320 seconds 
throughout the procedure. Catheters were introduced in the LA through the long sheath that was 
systematically withdrawn back to the right atrium after the positioning of the catheters in the LA. 
As far as concerning the acute efficacy, we decided to validate the supposed PVI obtained with 
the nMARQ
TM
 catheter by using a multipolar catheter (Lasso, BiosenseWebster, Diamond Bar, 
USA) to map all the PVs at the baseline and after the PVI. At the beginning of the procedure, 
using the CARTO 3 system (Biosense Webster, Diamond Bar, USA), a fast electroanatomic map 
was created by nMARQ
TM
 and subsequently merged with the 3D MRI shell. Ablation endpoint 
was the PVI, defined by a complete elimination or dissociation of PV potentials. The nMARQ
TM
 
was positioned at the ostium of each PV guided by 3D LA reconstruction. In order to avoid the 
phrenic palsy, before delivering RF at the right-sided veins ostium, pacing at high output (10 
mA) was performed from each nMARQ
TM
 electrodes to exclude the phrenic nerve capture. In 
case of diaphragm capture, the local site was first tagged and the corresponding electrodes were 
switched off during the RF delivery. At the end of PVI, validated according to nMARQ
TM
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signals, Lasso catheter was re-advanced into the LA in order to confirm the effective PVI. If this 
target was not achieved, the nMARQ
TM
 catheter was re-advanced at the PVs ostia to deliver 
further RF pulses aiming PVI. If PVI was not confirmed by Lasso mapping after this second 
round of multiple multielectrodes RF delivery by the nMARQ
TM
, a 3.5-mm tip open irrigated 
catheter (SmarthTouch Thermocool, Biosense Webster Inc, Diamond Bar, California) was 
inserted through the same transseptal hole and used to complete the PVI.  At the end of the 
procedure, after ruling out any pericardial effusion by echocardiogram, heparin infusion was 
started and titrated to maintain an activated partial thromboplastin time value of 60–80 seconds. 
The patient was discharged home bridging warfarin and LMWH (1 mg/kg BD until INR was ≥ 
2) the day after. 
nMARQ
TM
 catheter and RF delivery details 
The nMARQ
TM 
system combines the 3D magnetic navigation system and multielectrode open-
irrigated ablation technology. The main elements are: the nMARQ
TM
 circular ablation catheter, 
the nMARQ
TM
 Multichannel generator and a dedicated software interface of Carto3
®
 system. 
The circular catheter has three magnetic sensors placed on the loop to allow the visualization on 
Carto3
® 
system and consists of a 7.6 F shaft catheter, which has an 8.4F circular loop at the distal 
part of the shaft with centered helical design and variable diameter (20-35 mm). Ten irrigated 
ring electrodes (10 irrigation holes, 3mm length, 4mm inter-electrode spacing) are contained on 
the loop of the catheter that is internally designed to assure the same irrigation flow per each 
electrode. An irrigation pump (Cool Flow
®
, Biosense Webster Inc, Diamond Bar, California) is 
used to control the heparinized saline irrigation (4mL/min during mapping, 60mL/min during 
ablation). A thermocouple is welded to each electrode on the outer edge of the loop. The circular 
catheter is connected to the nMARQ
TM
 Multichannel generator that has 10 channels, one for 
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each electrode. Each channel acts independently and one does not interact with the other in order 
to avoid any energy transferring. The generator may operate in unipolar or bipolar mode and 
continuously monitors impedance, temperature at each electrode and power delivered by each 
electrode/pair. The modality of the ablation is temperature control mode. During ablation, the 
generator controls the temperature of each electrode involved and reduces the power if the target 
temperature exceeded. In our study, after catheter placement at the desired location, RF energy 
was delivered only in unipolar mode, simultaneously from 1 up to 10 electrodes at the sites 
presenting PV potentials. The maximum duration of each multielectrodes application session was 
40 sec. The target temperature was set to 45°C. The power delivered was set to 20W, decreased 
to 18W in the posterior wall in order to reduce the risk of esophageal injury, and increased up to 
25W in the left lateral ridge and in the reconnection sites. In case of suspicion of electrodes 
overlapping due to a small catheter loop seen on  fluoroscopy or 3D catheter visualization of the 
CARTO3 system and the presence of artifacts on endocardial signals, RF energy was delivered 
only through one of them, in order to avoid any energy cross-talk that may favor over-heating 
and thrombus formation
10,11
.  
 
Summary of specific techniques aiming to reduce the incidence of periprocedural 
complication with the use of nMARQ
TM
 
Previous experiences with the use of PVAC (pulmonary vein ablation catheter-PVAC, Ablation 
Frontiers, Inc., Carlsbad, CA, USA)
8,10,11
 and with the use of nMARQ
TM 5,7
 showed that specific 
procedural settings correlated with the incidence of embolic complications. Based on these 
considerations the following work-flow aiming to reduce periprocedural complications was 
instituted:  
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1. the procedures were performed on intravenous unfractionated heparin (UFH) to keep 
ACT >320 seconds, monitored every 30 min. UFH (100 UI/Kg) was administered  as 
follows: 1/3 after the femoral access and the remaining 2/3 immediately after the 
transseptal puncture.   
2. Catheters introduction and withdrawal were performed always aspirating from the sheath 
during their manipulation.  
3. Transseptal sheath was continuously perfused with heparinized solution and it was 
systematically withdrawn back to the right atrium after LA catheters positioning.  
4. RF energy was delivered only in unipolar mode. 
5. In case of distal and proximal nMARQTM electrodes overlapping, RF energy was 
delivered only through one of them, in order to avoid any energy cross-talk that may 
favor over-heating and thrombus formation
10,11
.  
6. The maximum duration of each multielectrode application session was set to no more 
than 40 sec.  
7. The target temperature was set to 45°C.  
8. The power delivered was set to 20W and decreased to 18W in the posterior wall  in order 
to reduce the risk of esophageal injury,  
9. The electrodes showing the absence of heating over 36°C or reaching less than 10 Watt 
were turned off. 
10. Pacing at high output (10 mA) was performed from each nMARQTM electrodes at the 
right-sided veins ostium, before RF delivery, in order to avoid the phrenic nerve palsy. 
Therefore the electrodes showing diaphragm capture, were switched off during RF 
delivery. 
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Follow up 
Follow-up visits were scheduled at 3 and 6 months with physical examination, ECG, and 24-hour 
Holter monitoring. All the patients were encouraged to document any symptoms suggestive for 
AF/atrial tachycardia recurrence by a 12-lead ECG. After the ablation procedure, oral 
anticoagulant therapy (OAT) was maintained for at least 3 months. Thereafter, clinical decision 
about OAT interruption/continuation was made according to CHA2DS2-VASc score. The 
antiarrhythmic drugs (AADs) were continued for 12 weeks after the procedure, and then stopped 
if no recurrences occurred. 
 
Statistical Analysis 
Categorical variables are reported as count and percentages, while continuous variables as mean 
and standard deviations (SD). Comparison was tested in cross tabulations tables by means of the 
Pearson Chi-Square or Fisher’s Exact Test and by one-way ANOVA respectively for categorical 
and continuous variables. A two sided p-value <0.05 was considered statistically significant. All 
analyses were performed with SPSS 17.0 (SPSS Inc, Chicago, IL, USA). 
 
Results 
Out of 25 patients with paroxysmal AF enrolled, 19 (76%) were male with a mean age of 57±13 
years. Three (12%) patients showed ischemic heart disease while systemic hypertension was 
present in 13 (52%). The mean LA antero-posterior diameter was 44±8 mm while the mean left 
ventricular ejection fraction (LVEF) was 61±6%. A patent foramen ovale was found in 2 patients 
(8%). CHA2DS2-VASc score was 0 in 7 (28%), 1 in 9 (36%), ≥ 2 in 9 (36%) patients. The 
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neurological examination performed before ablation was normal in all the patients. Details about 
clinical characteristics are summarized in table 1.  
Feasibility and procedural details  
The ablation procedure was feasible in all the patients (Fig.1).  The nMARQ
TM
 catheter was 
easily manoeuvred without requiring the use of a steerable sheath in all the patients. 
Procedural details, including fluoroscopic and procedural times at different ablation steps, are 
summarized in table 2 while table 3 shows, for each vein, overall RF time, mean power and 
mean number of active electrodes. Nineteen out of 25 enrolled patients showed 4 PVs, 2 a left 
common trunk, and 4 patients had a right middle PV. In these latter patients, the anatomical 
encircling around the right superior and/or inferior PVs allowed to electrically isolate the right 
middle PV using the nMARQ
TM
 only (Fig.2). Overall, the mean RF time was 14.95 min while 
the mean power was 18.07 W and the mean number of activated electrodes was 6.62 for each 
vein. No significant difference among veins in term of procedural parameters considered was 
observed except for a longer RF time needed to achieve PVI in left superior PV (LSPV) and right 
superior PV (RSPV) when compared to left inferior PV (LIPV) (p=0.019) and right inferior PV 
(RIPV) (p=0.011), respectively. 
Acute success 
After a first round of several multielectrodes RF deliveries with the nMARQ
TM
 at each PV ostia 
obtaining the supposed PVI, Lasso catheter  mapping confirmed the PVI in 80 (78%) out of 102 
PVs. In the remaining 22 (22%),  Lasso mapping still demonstrated venoatrial connection and 
further nMARQ
TM
 RF applications were required at the LSPV in 5, LIPV in 4, RIPV in 6, and 
RSPV in 7 patients to obtain PVI). 
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At the end of the ablation procedure, PVI obtained with the use of the nMARQ
TM
 only and 
confirmed with the Lasso mapping, was achieved in 100 out of 102 (98%) identified and targeted 
PVs and in 24 out of 25 (96%) treated  patients. In the remaining patient, despite two rounds of 
multielectrodes RF delivery attempts with nMARQ
TM  
catheter, a residual conduction gap still 
remained in the area of the ridge between LSPV and left atrial appendage (LAA). PVI was safely 
and effectively achieved using a 3.5-mm tip open-irrigated catheter.  Moreover, in the same 
patient, phrenic nerve capture was observed in a quite large area around the anterior and inferior 
aspect of  RSPV ostium and antrum (Fig. 3). PVI of this RSPV was obtained with an anatomy-
tailored point-by-point ablation strategy using the 3.5-mm tip open-irrigated catheter. 
Safety outcome 
Out of 25 procedures performed no major complications were observed. Post-procedural cerebral 
DW-MRI did not show any new SCI in all the patients. Only 3 groin hematomas occurred. 
Six-months follow up 
All patients completed the six-month follow up. No late adverse events (including  cerebral 
thromboembolic events) were reported. Out of 25 patients 17 (68%) were in  sinus rhythm and 
free from symptomatic or documented asymptomatic atrial arrhythmias, without AADs. Of the 
remaining 8 patients, 3 had documented AF episodes, 2 had symptomatic episodes without 
ECG/ECG Holter documentation and 3 had atypical atrial flutter.  
 
Discussion 
The major findings of the present study are the followings: 
- PVI with the nMARQTM catheter seems feasible with procedural and fluoroscopy times 
similar or even inferior to those reported with other existing ablation systems. 
nMARQ
TM
 ablation 
13 
 
- The acute success of the procedure is high since PVI confirmed by Lasso mapping has 
been achieved in 100 out of 102 (98%) targeted PVs while in the remaining two veins 
further conventional RF delivery through a standard open-irrigated ablation catheter was 
necessary. However, the nMARQ
TM
 catheter was able to predict PVI only in 78% of PVs. 
This finding may influence the outcome of the procedure if performed without the Lasso 
catheter validation. 
- Our preliminary data showed that nMARQTM catheter appears to be safe with no major 
procedural complications. In particular, applying a specific procedural work-flow, no new 
SCI were detected by post-ablation brain MRI.  
“Point-by-point” ablation for PVI using conventional irrigated catheters is now widely used.12 
However, the procedure still requires experienced operators to create reliable contiguous 
transmural lesions and, according to these limitations, PVI results are not completely 
reproducible and vary among different centres. In order to overcome all these limitations,  
simultaneous multipolar ablation catheters have been introduced in clinical practice. The last of 
these catheters is the nMARQ
TM
, a new multipolar mapping and ablation catheter using an open-
irrigated RF ablation technology and integration into the CARTO3 system. Previous studies
 
reported that AF ablation by the use of nMARQ
TM
 is  feasible and represents  a reliable 
alternative for PVI with a high acute success rate.
5,6
  
Our experience showed similar results in terms of procedural times and acute success rate. 
Comparing the procedural time between the  “point by point” ablation technique and the 
nMARQ
TM
 ablation in our experience, no reduction was seen. It can be explained by our study 
protocol that imply extra procedural time due to the use of Lasso catheter mapping to validate the 
supposed PVI by the nMARQ
TM
. Thus, considering the learning curve and the avoidance of the 
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use of the Lasso catheter mapping in standard procedures, a further reduction of the procedural 
time may be expected. In addition, the manoeuvrability of the catheter was satisfactory  since 
PVI was obtained in all the cases without the use of steerable sheath in contrast to other 
experiences
5,6,13
. It is well known that PVs anatomy variability is remarkable
14
 and, because of 
that, the use of circular multipolar ablation catheter may present some limitations. Nevertheless, 
in our study, the nMARQ
TM 
catheter allowed us to achieve PVI in all the patients but 1 (96%).  In 
this patient, LSPV was not isolated due to the impossibility to achieve a transmural lesion at the 
ridge between the left PVs and the LAA with the nMARQ
TM
  and additional “point-by-point” 
ablation was required. Furthermore, phrenic nerve capture was also demonstrated in a quite large 
area around the RSPV antrum, so that, despite several attempts, a safe and complete PVI with the 
nMARQ
TM 
catheter was not achieved and conventional ablation was needed to tailor the lesion 
line according to this specific anatomy.  
An important limit of the nMARQ
TM
 catheter pointed out by our results is that it was able to 
predict PVI only in 78% of PVs according to the Lasso catheter mapping. The evidence of a 
discordance between nMARQ
TM
 and Lasso recording has been reported also by Rosso et al
13
. 
Possible explanations may be the difference in inter-electrode spacing, the electrodes size and 
more proximal position in the PVs ostia of the nMARQ
TM
 that may influence the endocardial 
electrograms characteristics. Further studies are necessary to evaluate the long term outcome of 
PVI obtained by the use of the nMARQ
TM
 only in order to assess the impact of confirmation of 
PVI with Lasso mapping on the procedural outcome.  
Regarding the X-ray exposure it should be considered that the nMARQ
TM
 technology, combining 
ablation capability with the 3D navigation, allows to visualize the catheter and consequently to 
maneuver it without the need of fluoroscopy. In our series the  mean total X-ray time was 
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1.8'±2”, similar to that previously published15 with conventional “point-by-point” RF ablation.  
Fluoroscopy was used almost only for the transseptal puncture and the initial positioning of the 
catheters, while the combination with the CARTO 3 system allowed to perform mapping and RF 
delivery fluoroless. This result has an important clinical implication for the reduction of 
fluoroscopy exposure for the patient and medical staff.  
Recently much attention has been raised regarding the occurrence of post-AF ablation SCI
8. 
 
With the use of multipolar non irrigated RF ablation catheters, PVAC, post-ablation SCI were 
detected in 38.9% of the cases
3
. Similar incidence ( 33%) has been reported by Deneke et al
5
 
using the nMARQ
TM
. Several periprocedural variables may play a potential role
16
. Using a 
porcine ablation model, Haines et al
10
 found that microemboli and microbubbles formation with 
PVAC were more common in the following settings: (1) bipolar over unipolar RF delivery; (2) 
during catheter introduction and manipulation; (3) during energy delivery with the overlap of 
proximal and distal electrodes. The results of a recent trial
8
 demonstrated that, performing 
ablation with a careful attention to avoid the above mentioned procedural settings
,10,11,16
, the rate 
of SCI with PVAC decreased dramatically to 1.7%. Applying  the same procedural precautions, 
as described in the methods sections, in our series  no SCI were detected by post-ablation DW 
MR, in contrast with the results reported by Deneke et al.
5
  Possible explanations of this 
difference may be: 1) longer total RF time (19’ vs 14.95’); 2) lower ACT level (334” vs 372”); 3) 
the use of the steerable sheath left in the LA during all the procedure and 4) possible 
simultaneous RF delivery when the proximal and distal electrodes overlapped
6
 (Deneke
5
 did not 
specify if the interaction between electrodes 1 and 10 was avoided). 
Deneke
7
 also reported the occurrence of  esophagopericardial fistula with a fatal outcome after 
an uneventful ablation of atrial fibrillation using the nMARQ
TM  
catheter. Furthermore, the same 
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authors reported also 33% of esophageal lesions detected by endoscopy.
5
 This complication was 
attributed to the use of high RF power in the posterior  wall. In our series we declined the use of 
esophageal temperature monitoring because of a possible causal connection between 
multielectrode ablation and esophageal lesion by passive heating of the temperature probe.
17
 
However, for safety reason, we delivered  a maximum of 18 watts RF energy in the posterior 
wall for no more than 40 seconds.  
Finally, in our study, with the use of the nMARQ
TM  
catheter a short-term success rate of 68% 
was achieved  without AADs. However, our short-term follow up does not allow any firm 
conclusion and the outcome of the procedure needs to be assessed in further studies with longer- 
follow-up and with more accurate detection tools to exclude asymptomatic arrhythmias episodes. 
 
Study limitations 
This is a study with a limited sample size and a short follow up. Moreover, the follow-up was 
carried out only on a clinical basis, so that asymptomatic AF episodes may be missed. 
Secondly, our acute and short term outcome cannot be attributed only to the use of the 
nMARQ
TM
  technology because, in our study protocol, the Lasso catheter was used to confirm 
PVI. In addition, in one patient the use of the standard 3.5-mm tip open irrigated catheter was 
needed to complete PVI. 
Another consideration regards the uncertainty of re Lasso recordings related to our study 
protocol since Lasso and nMARQ
TM
 signals were not recorded simultaneously, but in temporal 
sequencing. 
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Moreover, another limitation is that  the procedure was not performed with the widely used on-
warfarin protocol, but with the bridge protocol between warfarin and  LMWH with intra-
procedural heparin infusion.  
Finally, esophageal lesions were not assessed with endoscopy.  
 
Conclusions 
The limited size of our patient population does not allow any firm conclusion. However, our 
preliminary experience demonstrated the feasibility, the safety and  the good acute procedural 
success of the PVI performed with the  nMARQ
TM  
catheter. 
In addition an important result of our study is the complete absence of periprocedural SCI, in 
contrast with other experiences
5
 using the same ablation catheter. This finding underlies the 
importance of following a specific and careful procedural workflow.  
Our preliminary results need to be confirmed with long-term studies. 
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Table 1.  Baseline characteristics of enrolled patients.  
Variables  
Number of patients 25 
Gender (male) 19 (76%) 
Age (years) 57±13 
BMI (Kg/m2) 26±3 
Ischemic heart disease 3 (12%) 
Hypertension 13 (52%) 
Diabetes 1 (4%) 
Dyslipidemia  10 (40%) 
Dysthyroidism 6 (24%) 
First AF (months) 44±46 
Number of failed AADs 2 (1-5) 
CHA2DS2-VASc score 
0 
1 
≥2 
 
7 (28%) 
9 (36%) 
9 (36%) 
Anticoagulation: 
Oral anticoagulant therapy  
Aspirin 
None 
 
15 (60%) 
8 (32%) 
2 (8%) 
LVEF (%) 61±6 
LA APd (mm)  44±8 
Patent Foramen Ovale 2 (8%) 
PVs anatomy: 
Left common trunk 
Right middle PV 
4 PVs 
 
2 (8%) 
4 (16%) 
19 (76%) 
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AADs, antiarrhythmic drugs; AF, atrial fibrillation; APd, antero-posterior diameter; BMI, 
Body Max Index; LA, left atrium; LVEF, left ventricular ejection fraction; PV, Pulmonary 
vein 
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Table 2. Procedural variables.  
Variables  
Total procedural time (min) 131±49 
Total fluoro time (min) 1.8±2 
Catheter placement time (min) 29±16 
Fluoro time during catheter placement (min) 1.5±1.8 
Time of LA mapping (min) 11±5 
Fluoro time during LA mapping (min) 0.2±0.3 
Mean RF time (min) 14.9±3.7 
Fluoro time during RF (sec) 2±9 
Mean ACT (sec) 372±40 
Irrigation volume (ml) 1603±433 
 
ACT, activated clotting time; LA, left atrium; RF, radiofrequency;  
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Table 3. Radiofrequency delivery details using nMARQ
TM
 catheter 
 
 
Pulmonary 
Vein 
 
n 
Parameters Mean 
  Radiofrequency time (min) 4.03 
LSPV 23 Mean Power (W) 17.56 
  Mean n°of active electrodes 6.94 
    
  Radiofrequency time (min) 2.84 
LIPV 23 Mean Power (W) 18.34 
  Mean n°of active electrodes 6.15 
    
  Radiofrequency time (min) 5.07 
LCT 2 Mean Power (W) 16.79 
  Mean n°of active electrodes 8.55 
    
  Radiofrequency time (min) 4.79 
RSPV 25 Mean Power (W) 17.93 
 +RMPV  3 Mean n°of active electrodes 6.33 
    
  Radiofrequency time (min) 3.26 
RIPV 25 Mean Power (W) 18.29 
 +RMPV 1 Mean n°of active electrodes 7.13 
    
  Radiofrequency time (min) 14.95 
Total 102 Mean Power (W) 18.07 
  Mean n°of active electrodes 6.62 
 
LCT, left common trunk; LIPV, left inferior pulmonary vein; LSPV, left superior pulmonary 
vein; RIPV: right inferior pulmonary vein; RMPV, right middle pulmonary vein; RSPV, right 
superior pulmonary vein. 
 
